¼¼°èÀÇ Á¤¸Æ³» ÁÖÀÔ ÆßÇÁ ½ÃÀå
Intravenous Infusion Pumps
»óǰÄÚµå : 1777372
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 307 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,222,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,666,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Á¤¸Æ³» ÁÖÀÔ ÆßÇÁ ½ÃÀåÀº 2030³â±îÁö 85¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 60¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â Á¤¸Æ³» ÁÖÀÔ ÆßÇÁ ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 5.8%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 85¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¿ë·®Çü ÁÖÀÔ ÆßÇÁ´Â CAGR 5.1%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 25¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Àν¶¸° ÁÖÀÔ ÆßÇÁ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 5.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 16¾ï ´Þ·¯, Áß±¹Àº CAGR9.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Á¤¸Æ³» ÁÖÀÔ ÆßÇÁ ½ÃÀåÀº 2024³â¿¡ 16¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 17¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 9.0%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 2.9%¿Í 5.7%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.8%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ Á¤¸Æ³» ÁÖÀÔ ÆßÇÁ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Á¤¸Æ³» ÁÖÀÔ ÆßÇÁ°¡ ȯÀÚ Ä¡·á¸¦ ¾î¶»°Ô º¯È­½Ã۰í Àִ°¡?

Á¤¸Æ³» ÁÖÀÔ ÆßÇÁ ½ÃÀåÀº °íÁ¤¹Ð ¾à¹° Àü´Þ, ÇコÄɾî ÀÚµ¿È­, ¼ö¾× ±â¼ú ¹ßÀü¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ Å« ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. Á¤¸Æ³» ÁÖÀÔ ÆßÇÁ´Â ¼ö¾×, ¾à¹°, ¿µ¾çºÐÀ» ȯÀÚÀÇ Ç÷·ù¿¡ Á÷Á¢ ÁÖÀÔÇÏ´Â µ¥ »ç¿ëµÇ´Â Áß¿äÇÑ ÀÇ·á±â±âÀÔ´Ï´Ù. º´¿ø, ¿Ü·¡¼ö¼ú¼¾ÅÍ, ÀçÅÃÀÇ·á, ÁßȯÀÚ½Ç(ICU) µî¿¡¼­ Áö¼ÓÀûÀÎ ¾à¹° ÁÖÀÔ, È­Çпä¹ý, ÅëÁõ °ü¸®, ¼öºÐ º¸Ãæ ¿ä¹ýÀÌ ÇÊ¿äÇÑ °æ¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

´ç´¢º´, ¾Ï, ½ÉÇ÷°ü Áúȯ µî ¸¸¼ºÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Á¤¸ÆÁÖÀÔÆßÇÁ´Â Àå±âÀûÀΠȯÀÚ °ü¸®¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½º¸¶Æ® ÁÖÀÔ ÆßÇÁ, ¹«¼± ¿¬°á, AI¸¦ ÅëÇÑ ¿ë·® Á¶Àý°ú °°Àº ±â¼ú Çõ½ÅÀº º´¿øÀÇ ¿öÅ©Ç÷οì, ȯÀÚ ¾ÈÀü, ¾à¹° Åõ¿©ÀÇ Á¤È®¼º¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù.

Äڷγª19 »çÅ´ Á¤¸ÆÁÖÀÔÆßÇÁÀÇ Ã¤ÅÃÀ» ´õ¿í °¡¼ÓÈ­½ÃÄ×°í, º´¿øÀº °£È£»çÀÇ ¾÷¹« ºÎ´ãÀ» ÃÖ¼ÒÈ­Çϰí, °¨¿° °ü¸®¸¦ °­È­Çϸç, ÁßȯÀÚ½Ç È¯°æ¿¡¼­ ȯÀÚ °ü¸®¸¦ ÃÖÀûÈ­Çϱâ À§ÇØ ÀÚµ¿È­µÈ ¿ø°Ý ¸ð´ÏÅ͸µ ¼ö¾× ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ Á÷¸éÇÏ°Ô µÇ¾ú½À´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü°¡ ÀÚµ¿È­, ȯÀÚ ¾ÈÀü ¹× µðÁöÅÐ ÀÇ·á ½Ã½ºÅÛ°úÀÇ ÅëÇÕÀ» °è¼Ó ¿ì¼±½ÃÇÔ¿¡ µû¶ó ÁÖÀÔ ÆßÇÁ ½ÃÀåÀº ÇâÈÄ ¸î ³â µ¿¾È ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÁÖÀÔ ÆßÇÁ ½ÃÀåÀ» °ßÀÎÇÏ´Â ÁÖ¿ä µ¿ÇâÀº?

ÁÖÀÔ ÆßÇÁ ½ÃÀå¿¡¼­ °¡Àå Çõ½ÅÀûÀÎ Æ®·»µå Áß Çϳª´Â ½º¸¶Æ® ÁÖÀÔ ÆßÇÁÀÇ ºÎ»óÀÔ´Ï´Ù. ÀÌ AI ±â¹Ý ÇÁ·Î±×·¡¹ÖÀÌ °¡´ÉÇÑ ÁÖÀÔ ½Ã½ºÅÛ¿¡´Â Åõ¾à ¿À·ù °¨¼Ò ½Ã½ºÅÛ(DERS), ½Ç½Ã°£ ¾à¹° ¶óÀ̺귯¸®, ¹«¼± ¿¬°áÀÌ ÇÔ²² Á¦°øµÇ¾î ÀÎÀû ¿À·ù¸¦ ÁÙÀ̸鼭 Á¤È®ÇÑ ¾à¹° Åõ¿©¸¦ º¸ÀåÇÕ´Ï´Ù. ½º¸¶Æ®ÆÊÇÁ´Â ÀüÀÚÀǹ«±â·Ï(EHR) ¹× ÀÓ»ó ÀÇ»ç°áÁ¤Áö¿ø½Ã½ºÅÛ(CDSS)°úÀÇ ÅëÇÕÀÌ ÁøÇàµÇ°í ÀÖÀ¸¸ç, ¿öÅ©Ç÷οìÀÇ ÀÚµ¿È­¸¦ °³¼±Çϰí Åõ¾àÀÇ ÃÖÀûÈ­¸¦ µµ¸ðÇϰí ÀÖ½À´Ï´Ù.

¶Ç ´Ù¸¥ Å« È帧Àº ÀçÅà ġ·á¸¦ À§ÇÑ ¿Ü·¡¿ë ÁÖÀÔ ÆßÇÁÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ÀçÅÃÀÇ·á¿Í ¿Ü·¡Áø·á°¡ º¸ÆíÈ­µÇ¸é¼­ ¸¸¼ºÁúȯ °ü¸®, È­Çпä¹ý, ÅëÁõ¿ÏÈ­ Ä¡·á µî¿¡ °¡º±°í ÈÞ´ë°¡ °¡´ÉÇÑ ¿þ¾î·¯ºí ¼ö¾×ÆßÇÁ°¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ÀüÅëÀûÀÎ º´¿ø ¿ÜÀÇ Àå¼Ò¿¡¼­ Ä¡·á¸¦ ¹Þ´Â °³ÀÎÈ­µÈ ȯÀÚ Áß½ÉÀÇ Ä¡·á ¸ðµ¨·Î ÀüȯÇÏ´Â °Í°ú ÀÏÄ¡ÇÕ´Ï´Ù.

¹«¼± ¸ð´ÏÅ͸µ°ú IoT Áö¿ø ÁÖÀÔ ÆßÇÁÀÇ ÅëÇÕ ¶ÇÇÑ ¾÷°è¿¡ Çõ¸íÀ» ºÒ·¯ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ÃֽŠÁÖÀÔ ÆßÇÁ´Â º´¿ø ³×Æ®¿öÅ© ¹× Ŭ¶ó¿ìµå ±â¹Ý Ç÷§Æû¿¡ ½Ç½Ã°£À¸·Î µ¥ÀÌÅ͸¦ Àü¼ÛÇÏ¿© ¼ö¾× ¼Óµµ ¿ø°Ý ¸ð´ÏÅ͸µ, Åõ¾à·® ºÒÀÏÄ¡ Á¶±â ¹ß°ß, À¯Áö º¸¼ö ¿¹Áö °æ°í¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ ±â¼úÀº ȯÀÚÀÇ ¾ÈÀü¼ºÀ» ³ôÀ̰í, °£È£»çÀÇ ºÎ´ãÀ» ÁÙÀ̸ç, Åõ¾à ¿À·ù¸¦ ÃÖ¼ÒÈ­ÇÕ´Ï´Ù.

¶ÇÇÑ, ·Îº¿ º¸Á¶ ÁÖÀÔ ÆßÇÁ¿Í AI¸¦ Ȱ¿ëÇÑ Åõ¾à ¾Ë°í¸®ÁòÀ» °³¹ßÇÏ¿© ¾à¹° Åõ¿©ÀÇ Á¤È®µµ¸¦ ³ôÀ̰í, °ú·® Åõ¿©ÀÇ À§ÇèÀ» ¹æÁöÇϰí ÀÖ½À´Ï´Ù. AI¸¦ Ȱ¿ëÇÑ ¼ö¾× ½Ã½ºÅÛÀº ȯÀÚÀÇ ¹ÙÀÌÅ», ¾à¹° »óÈ£ÀÛ¿ë, °ú°Å Åõ¾à ÆÐÅÏÀ» ºÐ¼®ÇÏ¿© ƯÈ÷ ÁßȯÀÚ Ä¡·á ¹× ¸¶Ãë °ü¸®¿¡¼­ ¼ö¾× ¼Óµµ¸¦ µ¿ÀûÀ¸·Î Á¶Á¤ÇÕ´Ï´Ù.

¶Ç ´Ù¸¥ »õ·Î¿î Æ®·»µå´Â ÀÏȸ¿ë ¹× ¹Ù´ÃÀ» »ç¿ëÇÏÁö ¾Ê´Â ÁÖÀÔ ½Ã½ºÅÛÀÇ °³¹ßÀÔ´Ï´Ù. °¨¿° °ü¸®, ±³Â÷ ¿À¿° ¹× ¹Ù´Ã¿¡ Âñ¸®´Â ºÎ»ó¿¡ ´ëÇÑ ¿ì·Á·Î ÀÎÇØ Á¦Á¶¾÷ü´Â ƯÈ÷ Á¾¾çÇÐ, ¸é¿ª ¿ä¹ý ¹× ½Å»ý¾Æ Ä¡·á ºÐ¾ß¿¡¼­ ÀÏȸ¿ë ¹× Æó¼â ½Ã½ºÅÛ ÁÖÀÔ ÆßÇÁ¸¦ µµÀÔÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀº º´¿øÀÇ ¾ÈÀü ÇÁ·ÎÅäÄݰú °¨¿° ¿¹¹æ °¡À̵å¶óÀο¡ ºÎÇÕÇÏ´Â ±â¼úÀÔ´Ï´Ù.

ÁÖÀÔ ÆßÇÁ ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â °úÁ¦´Â ¹«¾ùÀΰ¡?

Á¤¸ÆÁÖ»ç ±â¼úÀÇ ±Þ¼ÓÇÑ ¹ßÀü¿¡µµ ºÒ±¸Çϰí, ÀÌ ½ÃÀåÀº ³ôÀº Àåºñ ºñ¿ë, º¹ÀâÇÑ À¯Áöº¸¼ö, ±ÔÁ¦ À庮 µî ¿©·¯ °¡Áö ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. °¡Àå Å« ¿ì·Á´Â ½º¸¶Æ® ÁÖÀÔ ÆßÇÁ¿Í ÷´Ü ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ ³ôÀº ºñ¿ëÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Àåºñ´Â Á¤È®¼º°ú ¾ÈÀü¼ºÀ» ³ôÀÌ´Â ¹Ý¸é, º´¿ø ÀÎÇÁ¶ó, ±³À°, »çÀ̹ö º¸¾È¿¡ ¸¹Àº ÅõÀÚ¸¦ ÇÊ¿ä·Î Çϱ⠶§¹®¿¡ Áß¼Ò±Ô¸ðÀÇ ÀÇ·á½Ã¼³¿¡¼­´Â µµÀÔÀÌ ½±Áö ¾Ê½À´Ï´Ù.

¶Ç ´Ù¸¥ Áß¿äÇÑ °úÁ¦´Â ÁÖÀÔ ÆßÇÁÀÇ ¿À·ù¿Í ÀåºñÀÇ °íÀåÀÔ´Ï´Ù. ÇÁ·Î±×·¡¹Ö ¿À·ù, ±â°èÀû °íÀå, ¼ÒÇÁÆ®¿þ¾î °áÇÔÀ¸·Î ÀÎÇØ ½É°¢ÇÑ Åõ¾à ½Ç¼ö, °ú·® Åõ¿©, °ú¼Ò Åõ¿© »ç°í°¡ ¹ß»ýÇÏ¿© Á¦Ç° ȸ¼ö ¹× ±ÔÁ¦ ´ç±¹ÀÇ °¨½Ã¸¦ ÃÊ·¡Çϰí ÀÖ½À´Ï´Ù. FDA ¹× ±âŸ º¸°Ç ±â°üÀº ÁÖÀÔ ÆßÇÁ ¿ÀÀÛµ¿¿¡ ´ëÇÑ ¾ÈÀü °æ°í¸¦ ¹ßÇ¥Çϰí Á¦Á¶¾÷ü¿¡ ǰÁú °ü¸®, ¿À·ù ¹æÁö ¾Ë°í¸®Áò ¹× »ç¿ëÀÚ ±³À°À» °³¼±Çϵµ·Ï Ã˱¸Çϰí ÀÖ½À´Ï´Ù.

IoT¸¦ Áö¿øÇÏ´Â ¹«¼± ÁÖÀÔ ÆßÇÁ°¡ º¸ÆíÈ­µÇ¸é¼­ »çÀ̹ö º¸¾È À§Çù°ú µ¥ÀÌÅÍ Ãë¾à¼ºÀÌ ¶Ç ´Ù¸¥ °úÁ¦·Î ¶°¿À¸£°í ÀÖ½À´Ï´Ù. º´¿ø ³×Æ®¿öÅ©¸¦ ³ë¸®´Â ÇØÄ¿°¡ ¼ö¾× ÁÖÀÔ ¼Óµµ¸¦ Á¶ÀÛÇϰųª ȯÀÚ µ¥ÀÌÅ͸¦ À¯Ãâ½Ãų ¼ö ÀÖÀ¸¸ç, ÀÌ´Â ½É°¢ÇÑ °Ç°­ À§Çè°ú Ã¥ÀÓ ¹®Á¦·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. ÀÇ·á½Ã¼³Àº °­·ÂÇÑ »çÀ̹ö º¸¾È ÇÁ·ÎÅäÄÝ, ¾Ïȣȭ ±â¼ú, Á¤±âÀûÀÎ ¼ÒÇÁÆ®¿þ¾î ¾÷µ¥ÀÌÆ®¸¦ µµÀÔÇÏ¿© ¼ö¾× ÀåÄ¡¿¡ ´ëÇÑ »çÀ̹ö °ø°Ý °¡´É¼ºÀ» ¹æÁöÇØ¾ß ÇÕ´Ï´Ù.

ÀåºñÀÇ »óÈ£¿î¿ë¼º°ú º´¿ø IT ½Ã½ºÅÛ°úÀÇ ÅëÇÕÀÌ º¹ÀâÇÏ´Ù´Â Á¡µµ µµÀÔÀÇ °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¸¹Àº º´¿øµéÀÌ ¿©ÀüÈ÷ ±¸½Ä ÀüÀÚ ÀÇ·á ±â·Ï(EHR) ½Ã½ºÅÛÀ» »ç¿ëÇϰí Àֱ⠶§¹®¿¡ ½º¸¶Æ® ÁÖÀÔ ÆßÇÁ¸¦ ±âÁ¸ ÀÎÇÁ¶ó¿Í ¿øÈ°ÇÏ°Ô ÅëÇÕÇÏ´Â µ¥ ¾î·Á¿òÀÌ ÀÖ½À´Ï´Ù. ¼­·Î ´Ù¸¥ ÇコÄɾî Ç÷§Æû °£ÀÇ ¿øÈ°ÇÑ µ¥ÀÌÅÍ ±³È¯°ú ȣȯ¼ºÀ» º¸ÀåÇϱâ À§Çؼ­´Â Ç¥ÁØÈ­ ³ë·ÂÀÌ ÇÊ¿äÇÕ´Ï´Ù.

¶ÇÇÑ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ ¹× ±ÔÁ¤ Áؼö ¿ä±¸ »çÇ×ÀÌ ¾ö°ÝÇÏ¿© »õ·Î¿î ÁÖÀÔ ÆßÇÁ ¸ðµ¨ÀÇ µµÀÔÀÌ Áö¿¬µÇ°í ÀÖ½À´Ï´Ù. ÁÖÀÔ ÆßÇÁ´Â ¾ÈÀü¼º, ¿ë·® Á¤È®µµ, ¼ÒÇÁÆ®¿þ¾îÀÇ ½Å·Ú¼º¿¡ ´ëÇÑ ¾ö°ÝÇÑ FDA, CE(À¯·´), ISO(±¹Á¦Ç¥ÁØÈ­±â±¸)ÀÇ °¡À̵å¶óÀÎÀ» ÃæÁ·ÇØ¾ß ÇÕ´Ï´Ù. ½ÂÀÎ ÀýÂ÷¿¡ ½Ã°£ÀÌ ¿À·¡ °É¸®±â ¶§¹®¿¡ Çõ½ÅÀûÀÎ ¼ö¾× ÀåÄ¡ÀÇ ¿¬±¸°³¹ßºñ¿ë°ú ½ÃÀå Ãâ½Ã ½Ã°£ÀÌ Áõ°¡ÇÕ´Ï´Ù.

Á¤¸Æ³» ÁÖÀÔ ÆßÇÁ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

ÁÖÀÔ ÆßÇÁ ½ÃÀåÀÇ ¼ºÀåÀº ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, ÀÇ·á ±â¼úÀÇ ¹ßÀü, ¾à¹° Àü´Þ ÀÚµ¿È­¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁý´Ï´Ù. °¡Àå Å« ÃËÁø¿äÀÎ Áß Çϳª´Â ƯÈ÷ ÁßȯÀÚ Ä¡·á, Á¾¾çÇÐ, ½Å»ý¾Æ ÀÇ·á ºÐ¾ß¿¡¼­ Á¤È®Çϰí ÅëÁ¦µÈ ¾à¹° Åõ¿©ÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ¾ÈÀü ¸ÞÄ¿´ÏÁòÀ» °®Ãá ½º¸¶Æ® ÁÖÀÔ ÆßÇÁ´Â Åõ¾à ½Ç¼ö¸¦ ÁÙÀÌ´Â µ¥ µµ¿òÀÌ µÇ¸ç, ÁßȯÀÚ½Ç, ¼ö¼ú½Ç, ¼Ò¾Æº´µ¿°ú °°Àº °íÀ§Çè ȯ°æ¿¡¼­´Â ÇʼöÀûÀÔ´Ï´Ù.

ÀçÅà ¼ö¾×¿ä¹ýÀ̳ª ¿Ü·¡ ¼ö¾×¿ä¹ýÀÇ µµÀÔÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ Å« ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ´ç´¢º´, ¾Ï, ÀÚ°¡¸é¿ªÁúȯ µî ¸¸¼ºÁúȯ ȯÀÚµéÀº Àå±âÀûÀÎ ¼ö¾×¿ä¹ýÀ» ÇÊ¿ä·Î ÇÏ´Â °æ¿ì°¡ ¸¹±â ¶§¹®¿¡ º´¿ø ¹Û¿¡¼­ Ä¡·á¸¦ ÇÒ ¼ö ÀÖ´Â ÈÞ´ë¿ë ¹× Âø¿ëÇü ¼ö¾×ÆßÇÁ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ³ëÀÎ Àα¸ Áõ°¡¿Í ¿ø°Ý ÀÇ·á ¼­ºñ½º Áõ°¡´Â ÀÌ·¯ÇÑ Ãß¼¼¸¦ ´õ¿í ºÎÃß±â°í ÀÖ½À´Ï´Ù.

ºñ°æ±¸ ¿µ¾ç ¹× ÅëÁõ °ü¸® ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡µµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¿µ¾ç½ÇÁ¶, À§ÀåÀå¾Ö, ¼ö¼ú ÈÄ È¸º¹¿¡ ¾î·Á¿òÀ» °Þ´Â ȯÀÚµéÀº ÁÖÀÔ ÆßÇÁ¸¦ ÅëÇÑ Á¤¸Æ¿µ¾ç °ø±ÞÀÌ ÇÊ¿äÇϱ⠶§¹®¿¡ Ư¼ö °æÀå ¹× ºñ°æ±¸ ¼ö¾×ÀåÄ¡¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î, ȯÀÚ Á¦¾î ÁøÅëÁ¦(PCA) ÆßÇÁ´Â ¼ö¼ú ÈÄ ¶Ç´Â ¿ÏÈ­ Ä¡·á¿¡¼­ ¿ÀÇÇ¿ÀÀ̵带 »ç¿ëÇÏÁö ¾Ê´Â ÅëÁõ °ü¸®¸¦ À§ÇØ Àα⸦ ¾ò°í ÀÖ½À´Ï´Ù.

½ÅÈï ½ÃÀå¿¡¼­ÀÇ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê¿Í ÇコÄɾî ÀÎÇÁ¶ó Çö´ëÈ­ ÇÁ·ÎÁ§Æ®µµ ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ±¹°¡µéÀº ȯÀÚ Ä¡·á °­È­¿Í º´¿ø ³» ÇÕº´Áõ °¨¼Ò¸¦ À§ÇØ Ã·´Ü º´¿ø Àåºñ, µðÁöÅÐ Çコ ¼Ö·ç¼Ç, ½º¸¶Æ® ¼ö¾× ½Ã½ºÅÛ¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿Í ¾à¹° Àü´ÞÀÇ ºÎ»óÀ¸·Î À¯ÀüÀÚ Ä¡·á, ¸é¿ª ¿ä¹ý, Ç¥Àû ¾Ï Ä¡·á¸¦ À§ÇØ ¼³°èµÈ Ư¼ö ÁÖÀÔ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. º¹ÀâÇÑ »ý¹°ÇÐÀû Á¦Á¦ÀÇ ÆÄÀÌÇÁ¶óÀÎÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Á¦¾àȸ»ç´Â ÀÇ·á±â±â Á¦Á¶¾÷ü¿Í Çù·ÂÇÏ¿© Á¤¹ÐÇÑ ¾à¹° Åõ¿©¸¦ À§ÇÑ Â÷¼¼´ë ÁÖÀÔ ±â¼úÀ» °³¹ßÇϰí ÀÖ½À´Ï´Ù.

°á·Ð ÁÖÀÔ ÆßÇÁ ±â¼úÀÇ ¹Ì·¡

ÀÇ·á½Ã¼³, ÀçÅÃÄ¡·á ¼­ºñ½º Á¦°ø¾÷ü, Á¦¾àȸ»ç°¡ º¸´Ù ½º¸¶Æ®ÇÏ°í ¾ÈÀüÇϸç È¿À²ÀûÀÎ ¾à¹° Àü´Þ ½Ã½ºÅÛÀ» äÅÃÇÔ¿¡ µû¶ó ÁÖÀÔ ÆßÇÁ ½ÃÀåÀº Áö¼ÓÀûÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. AI, ·Îº¿°øÇÐ, µðÁöÅÐ Çコ ÅëÇÕÀÇ ±â¼ú Çõ½ÅÀÌ ÁøÇàµÊ¿¡ µû¶ó ÁÖÀÔ ÆßÇÁ´Â °³ÀÎ ¸ÂÃãÇü ÀÇ·á, ÀÚµ¿ ¾à¹° Åõ¿©, ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ¿¡¼­ Á¡Á¡ ´õ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ°Ô µÉ °ÍÀÔ´Ï´Ù.

±â±â ¾ÈÀü¼º, »çÀ̹ö º¸¾È, ±ÔÁ¦ Áؼö, º´¿ø°úÀÇ ¿øÈ°ÇÑ ÅëÇÕÀ» ¿ì¼±½ÃÇÏ´Â Á¦Á¶¾÷ü´Â ÁøÈ­ÇÏ´Â ¼ö¾× Ä¡·á ȯ°æ¿¡¼­ °æÀï ¿ìÀ§¸¦ Á¡ÇÒ ¼ö ÀÖÀ» °ÍÀÔ´Ï´Ù. Á¤¹Ð ±â¹Ý, Àúħ½À, Ä¿³ØÆ¼µå ¼ö¾× ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¼ö¾× Ä¡·áÀÇ ¹Ì·¡´Â ÀÚµ¿È­, ȯÀÚ Á᫐ ¼Ö·ç¼Ç, ÷´Ü µðÁöÅÐ Çコ »ýŰ迡 ÀÇÇØ Á¤ÀÇµÉ °ÍÀÔ´Ï´Ù.

ºÎ¹®

Á¦Ç°(¿ë·® ÁÖÀÔ ÆßÇÁ, Àν¶¸° ÁÖÀÔ ÆßÇÁ, ½Ã¸°Áö ÁÖÀÔ ÆßÇÁ, °æÀå ÁÖÀÔ ÆßÇÁ, ¿Ü·¡ ÁÖÀÔ ÆßÇÁ, ȯÀÚ Á¦¾îÁøÅë, À̽ÄÇü ÁÖÀÔ ÆßÇÁ, ±âŸ), ÀûÀÀ Áúȯ(È­Çпä¹ý, ´ç´¢º´, ¼ÒÈ­±âº´, ÁøÅë/ÅëÁõ °ü¸®, ¼Ò¾Æ°ú/½Å»ý¾Æ°ú, Ç÷¾× ³»°ú, ±âŸ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è µµ¸ÞÀÎ Àü¹®°¡·ÎºÎÅÍ Å¥·¹ÀÌÆ®µÈ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Intravenous Infusion Pumps Market to Reach US$8.5 Billion by 2030

The global market for Intravenous Infusion Pumps estimated at US$6.0 Billion in the year 2024, is expected to reach US$8.5 Billion by 2030, growing at a CAGR of 5.8% over the analysis period 2024-2030. Volumetric Infusion Pumps, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$2.5 Billion by the end of the analysis period. Growth in the Insulin Infusion Pumps segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 9.0% CAGR

The Intravenous Infusion Pumps market in the U.S. is estimated at US$1.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 9.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Intravenous Infusion Pump Market - Key Trends & Drivers Summarized

How Are Intravenous Infusion Pumps Transforming Patient Care?

The intravenous (IV) infusion pump market is experiencing significant growth due to the increasing demand for precision drug delivery, automation in healthcare, and advancements in infusion technology. IV infusion pumps are critical medical devices used to deliver fluids, medications, and nutrients directly into a patient’s bloodstream in controlled amounts. They play a vital role in hospitals, ambulatory surgical centers, home healthcare, and intensive care units (ICUs) for conditions requiring continuous drug infusion, chemotherapy, pain management, and hydration therapy.

With the rising prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disorders, IV infusion pumps have become essential for long-term patient management. Additionally, technological innovations such as smart infusion pumps, wireless connectivity, and AI-driven dosage adjustments are revolutionizing hospital workflows, patient safety, and drug administration accuracy.

The COVID-19 pandemic further accelerated the adoption of IV infusion pumps, as hospitals faced an increased demand for automated and remotely monitored infusion systems to minimize nurse workload, enhance infection control, and optimize patient management in ICU settings. As healthcare providers continue to prioritize automation, patient safety, and integration with digital health systems, the IV infusion pump market is expected to grow rapidly in the coming years.

What Are the Key Trends Driving the IV Infusion Pump Market?

One of the most transformative trends in the IV infusion pump market is the rise of smart infusion pumps. These AI-driven and programmable infusion systems come with dose error reduction systems (DERS), real-time drug libraries, and wireless connectivity, ensuring precise medication administration while reducing human errors. Smart pumps are increasingly being integrated with electronic health records (EHRs) and clinical decision support systems (CDSS) to improve workflow automation and optimize medication dosing.

Another major trend is the increasing adoption of ambulatory infusion pumps for home-based therapy. As home healthcare and outpatient treatment gain popularity, lightweight, portable, and wearable infusion pumps are being used for chronic disease management, chemotherapy, and pain relief treatments. This trend aligns with the shift toward personalized and patient-centric care models, where individuals receive treatment outside of traditional hospital settings.

The integration of wireless monitoring and IoT-enabled infusion pumps is also revolutionizing the industry. Modern IV infusion pumps transmit real-time data to hospital networks and cloud-based platforms, allowing remote monitoring of infusion rates, early detection of dosage discrepancies, and predictive maintenance alerts. This technology enhances patient safety, reduces nurse workload, and minimizes medication errors.

Additionally, robotic-assisted infusion pumps and AI-powered dosing algorithms are being developed to improve drug administration accuracy and prevent overdose risks. AI-driven infusion systems analyze patient vitals, drug interactions, and historical dosage patterns to adjust infusion rates dynamically, particularly in critical care and anesthesia management.

Another emerging trend is the development of disposable and needle-free infusion systems. Concerns over infection control, cross-contamination, and needle-stick injuries have driven manufacturers to introduce single-use and closed-system infusion pumps, particularly for oncology, immunotherapy, and neonatal care applications. These innovations align with hospital safety protocols and infection prevention guidelines.

What Challenges Are Impacting the IV Infusion Pump Market?

Despite the rapid advancements in IV infusion technology, the market faces several challenges, including high device costs, maintenance complexity, and regulatory hurdles. One of the biggest concerns is the high cost of smart infusion pumps and advanced drug delivery systems. While these devices enhance accuracy and safety, they require significant investment in hospital infrastructure, training, and cybersecurity, making adoption difficult for small and mid-sized healthcare facilities.

Another key challenge is infusion pump errors and device malfunctions. Programming errors, mechanical failures, and software glitches have resulted in serious medication errors, overdoses, and under-dosing incidents, leading to product recalls and regulatory scrutiny. The FDA and other health agencies have issued safety alerts regarding infusion pump malfunctions, prompting manufacturers to improve quality control, error prevention algorithms, and user training.

Cybersecurity threats and data vulnerabilities pose another challenge, as IoT-enabled and wireless infusion pumps become more common. Hackers targeting hospital networks could manipulate infusion rates or compromise patient data, leading to serious health risks and liability concerns. Healthcare facilities must implement robust cybersecurity protocols, encryption technologies, and regular software updates to prevent potential cyberattacks on infusion devices.

Complexity in device interoperability and integration with hospital IT systems also hinders adoption. Many hospitals still operate with legacy electronic health record (EHR) systems, making it difficult to seamlessly integrate smart IV pumps with existing infrastructure. Standardization efforts are needed to ensure smooth data exchange and compatibility across different healthcare platforms.

Additionally, stringent regulatory approvals and compliance requirements delay the introduction of new infusion pump models. IV infusion pumps must meet strict FDA, CE (Europe), and ISO (International Organization for Standardization) guidelines regarding safety, dosage accuracy, and software reliability. The lengthy approval process increases R&D costs and time-to-market for innovative infusion devices.

What Factors Are Driving the Growth of the IV Infusion Pump Market?

The growth in the IV infusion pump market is driven by several factors, including the rising prevalence of chronic diseases, advancements in medical technology, and increasing demand for automation in drug delivery. One of the biggest drivers is the growing need for precise and controlled medication administration, particularly in critical care, oncology, and neonatal care. Smart infusion pumps equipped with safety mechanisms help reduce medication errors, making them essential in high-risk environments such as ICUs, operating rooms, and pediatric wards.

Another major driver is the increasing adoption of home-based and ambulatory infusion therapy. Patients with chronic conditions such as diabetes, cancer, and autoimmune disorders often require long-term infusion therapy, leading to the rising demand for portable and wearable IV pumps that enable treatment outside hospital settings. The growing elderly population and the rise of telehealth services further support this trend.

The increasing demand for parenteral nutrition and pain management solutions is also propelling market growth. Patients suffering from malnutrition, gastrointestinal disorders, or post-operative recovery require intravenous feeding via infusion pumps, driving demand for specialized enteral and parenteral infusion devices. Similarly, patient-controlled analgesia (PCA) pumps are gaining popularity for opioid-free pain management in post-surgical and palliative care.

Government initiatives and healthcare infrastructure modernization projects in emerging markets are also fueling market expansion. Countries across Asia-Pacific, Latin America, and the Middle East are investing in advanced hospital equipment, digital health solutions, and smart infusion systems to enhance patient care and reduce hospital-acquired complications.

Furthermore, the rise of personalized medicine and biologic drug delivery is driving demand for specialized infusion systems designed for gene therapy, immunotherapy, and targeted cancer treatments. With the growing pipeline of complex biologic drugs, pharmaceutical companies are partnering with medical device manufacturers to develop next-generation infusion technologies for precision drug administration.

Conclusion: The Future of IV Infusion Pump Technology

The IV infusion pump market is poised for continued growth as healthcare facilities, home-based care providers, and pharmaceutical companies adopt smarter, safer, and more efficient drug delivery systems. With ongoing innovations in AI, robotics, and digital health integration, IV pumps will play an increasingly critical role in personalized medicine, automated drug administration, and remote patient monitoring.

Manufacturers that prioritize device safety, cybersecurity, regulatory compliance, and seamless hospital integration will gain a competitive edge in the evolving infusion therapy landscape. As demand for precision-based, minimally invasive, and connected infusion systems rises, the future of IV therapy will be defined by automation, patient-centric solutions, and advanced digital health ecosystems.

SCOPE OF STUDY:

The report analyzes the Intravenous Infusion Pumps market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Volumetric Infusion Pumps, Insulin Infusion Pumps, Syringe Infusion Pumps, Enteral Infusion Pumps, Ambulatory Infusion Pumps, Patient Controlled Analgesia, Implantable Infusion Pumps, Others); Disease Indication (Chemotherapy, Diabetes, Gastroenterology, Analgesia / Pain Management, Pediatrics / Neonatology, Hematology, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â